Enanta Pharmaceuticals, Inc. ENTA
NASDAQ · United States · Health Technology
$12.96+0.12 (+0.93%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
WATERTOWN, Mass., August 10, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.